Expert Ratings for Krystal Biotech
Portfolio Pulse from Benzinga Insights
Krystal Biotech (NASDAQ:KRYS) received 5 analyst ratings in the last quarter, with 2 bullish and 3 somewhat bullish, and none bearish. The 12-month average price target is $164.0, a 2.5% increase from the previous $160.00 target. Ratings are based on financial analysis and are subject to human error.
December 13, 2023 | 6:00 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Krystal Biotech has a positive outlook from analysts with an increased average price target of $164, suggesting confidence in the company's future performance.
The unanimous positive ratings from analysts, with an increased price target, indicate a strong bullish sentiment towards KRYS. This consensus could lead to increased investor confidence and a potential short-term rise in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100